. home.aspx


How attractive are Bio-similars for pharma companies?

September 20, 2019 / PETER WALLACE

Biosimilar therapies are copies of large-molecule, biologic drugs. They differ from generics in that they are not exact copies of the original drug but, rather, a similar molecule that delivers an equivalent clinical outcome to the branded drug. Where small molecule drugs comprise 10s of atoms, biologics (and biosimilars) comprise 10s of thousands of atoms.